Literature DB >> 8307768

Effect of perceived barriers on compliance with antihypertensive medication.

M A Richardson1, B Simons-Morton, J F Annegers.   

Abstract

Noncompliance with antihypertensive medication remains an obstacle to the management of hypertension, and despite research efforts over the past decade, the predictors of noncompliance remain unclear. According to values expectancy theory, individuals rationally choose noncompliance when the barriers or costs of treatment outweigh the expected benefits. Noncompliance, therefore, is likely to occur when net costs of treatment are high. Using a cross-sectional study design among subjects (n = 197) attending a specialized clinic for hypertension, we measured "net barriers" (costs), self-reported compliance, and possible determinants of noncompliance, including socio-demographics, the medical regimen, and locus of control. The effect of each quartile of the net barriers score (none, low, moderate, and high) on compliance, controlling for potential effect modifiers, was assessed using logistic regression modeling. Noncompliance (47%) was associated with younger age, higher salt use, longer duration of treatment, and higher levels of net barriers, but duration of treatment modified the effect of net barriers. Among subjects in short-term treatment, noncompliance increased with severity of net barriers suggesting a dose-response effect. In contrast, patients in long-term treatment showed no dose-response effect but a consistent association between noncompliance and levels of net barriers. Subjects at greater risk for noncompliance, however, were those who reported high net barriers, regardless of duration of treatment. Net barriers accounted for 50% of the noncompliance and appeared most important for patients who were younger or in the early stages of treatment. Implications for health care providers are discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8307768     DOI: 10.1177/109019819302000409

Source DB:  PubMed          Journal:  Health Educ Q        ISSN: 0195-8402


  11 in total

Review 1.  Noncompliance with antihypertensive therapy. Economic consequences.

Authors:  T L Skaer; D A Sclar; L M Robison
Journal:  Pharmacoeconomics       Date:  1996-01       Impact factor: 4.981

2.  Compliance and hypertension.

Authors:  F B Garfield; J J Caro
Journal:  Curr Hypertens Rep       Date:  1999-12       Impact factor: 5.369

3.  Development of a structural model explaining medication compliance of persons with schizophrenia.

Authors:  Mi A Seo; Sung Kil Min
Journal:  Yonsei Med J       Date:  2005-06-30       Impact factor: 2.759

4.  Predictors of refill non-adherence in patients with heart failure.

Authors:  Johnson George; Stephen J Shalansky
Journal:  Br J Clin Pharmacol       Date:  2006-10-31       Impact factor: 4.335

Review 5.  Medication non-adherence in the elderly: how big is the problem?

Authors:  Carmel M Hughes
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

6.  Using the health belief model to explain clinic appointment-keeping for the management of a chronic disease condition.

Authors:  J Mirotznik; E Ginzler; G Zagon; A Baptiste
Journal:  J Community Health       Date:  1998-06

7.  Testing the psychometric properties of the Medication Adherence Scale in patients with heart failure.

Authors:  Jia-Rong Wu; Misook Chung; Terry A Lennie; Lynne A Hall; Debra K Moser
Journal:  Heart Lung       Date:  2008 Sep-Oct       Impact factor: 2.210

8.  Predictors of medication adherence using a multidimensional adherence model in patients with heart failure.

Authors:  Jia-Rong Wu; Debra K Moser; Misook L Chung; Terry A Lennie
Journal:  J Card Fail       Date:  2008-05-27       Impact factor: 5.712

9.  Validation of a French version of the 8-item Morisky medication adherence scale in hypertensive adults.

Authors:  Virginie Korb-Savoldelli; Florence Gillaizeau; Jacques Pouchot; Emilie Lenain; Nicolas Postel-Vinay; Pierre-François Plouin; Pierre Durieux; Brigitte Sabatier
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-04-26       Impact factor: 3.738

Review 10.  Compliance with the treatment of hypertension: the potential of combination therapy.

Authors:  Serap Erdine
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-01       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.